Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13Rα2-Targeted CAR T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma
NCT04661384Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2021
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells in glioblastoma (GBM), ependymoma, medulloblastoma and 1 more, sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 15 years and Overall survival at 3 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells
03
Conditions
glioblastoma (GBM)ependymomamedulloblastomaleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04661384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661384.